Fig. 1From: Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancerRecurrence-free survival among 272 patients with estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer after neoadjuvant chemotherapy (solid line), and the 95 % confidence interval. Numbers of patients at risk are shown above the x-axis Back to article page